Go Pro
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:ARTL

Artelo Biosciences Q2 2026 Earnings Report

Artelo Biosciences logo
$1.14 -0.01 (-0.87%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.10 -0.04 (-3.51%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Artelo Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.72
Beat/Miss
N/A
One Year Ago EPS
N/A

Artelo Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Artelo Biosciences Announcement Details

Quarter
Q2 2026
Date
8/12/2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 11, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Artelo Biosciences Earnings Headlines

Artelo Biosciences Announces Preclinical Data Supporting ART26.12 for Osteoarthritis Pain with Reduced Gastric Damage Compared with Naproxen
July 16 at 9:11 AM  |  quiverquant.comQ
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
July 16 at 8:48 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328460/0/en/artelo-biosciences-announces-results-from-a-nonclinical-osteoarthritis-study-supporting-art26-12-as-a-potential-first-in-class-new-therapy-for-chronic-pain-conditions.html
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
 |  Porter & Company (Ad)
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
July 14 at 8:47 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326870/0/en/artelo-biosciences-issues-reminder-to-shareholders-to-vote-in-advance-of-annual-meeting-on-july-17-2026.html
Artelo Biosciences Announces ART27.13 Data Suggest Potential Benefit for Neuropathic Pain in Cancer Patients
July 13, 2026  |  quiverquant.comQ
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326230/0/en/artelo-biosciences-announces-positive-results-with-art27-13-in-a-nonclinical-model-of-paclitaxel-induced-peripheral-neuropathy.html
See More Artelo Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Artelo Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artelo Biosciences and other key companies, straight to your email.

About Artelo Biosciences

Artelo Biosciences (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia. In parallel, Artelo is advancing AB188, a topical formulation aimed at treating ocular surface diseases such as dry eye syndrome. Earlier-stage preclinical candidates are being explored for inflammatory and cardiometabolic indications, reflecting the versatility of Artelo’s platform technology in shaping molecular properties to target diverse disease pathways.

Founded as a Delaware corporation, Artelo Biosciences is headquartered in Cleveland, Ohio, and conducts research and development activities in the United States. The executive leadership team brings together expertise in medicinal chemistry, pharmaceutical development and regulatory strategy. Artelo continues to engage with key opinion leaders and strategic partners to support its pipeline through proof-of-concept studies and toward eventual regulatory filings.

View Artelo Biosciences Profile
Earnings Tools